UVA1 for Dyshidrotic Hand Eczema: What a 28-Patient Light-Treatment Trial Can Tell You
Light treatment can sound like one uniform option for eczema. In fact, the wavelength, dose, body area and diagnosis change the question. A small placebo-controlled study of UVA1 for dyshidrotic hand eczema provides a useful example of why the details should come before a decision.
A short, controlled trial in hand eczema
The primary study published in November 2003 randomized 28 patients to UVA1 irradiation or placebo. Active treatment used 40 joules per square centimeter, five times weekly for three weeks. That describes 15 planned treatment sessions. It is a clinic research schedule, not a safe exposure recipe for home lamps, sunbathing or tanning beds.
The authors used the Dyshidrotic Area and Severity Index, or DASI, and a visual analogue scale, or VAS. These assess different aspects of the disease; a score improvement is not automatically complete clearance, lasting remission or a patient’s ability to return to every activity.
| Study detail | Reported finding | Important limit |
|---|---|---|
| 28 patients; randomized, double-blind comparison | UVA1 was significantly better than placebo on DASI and VAS after weeks two and three | The accessible abstract does not provide numerical between-group effect sizes or confidence intervals |
| Individual skin findings | Scaling and affected area improved more with UVA1 | This is not a quantified universal clearance rate |
| IgE above 100 IU/mL versus normal IgE | No difference in response was found between these groups | A small subgroup comparison cannot establish that IgE never matters |
| Three-week treatment period | No side effects were observed | Short observation in a small study cannot establish long-term ultraviolet safety |
A positive result still leaves practical questions
This trial provides controlled evidence of short-term benefit. It does not answer how long the benefit persisted, which maintenance schedule was best or how UVA1 compared with today’s other hand-eczema options. The discussion here is based on the primary abstract, not an assertion that every detail of the full paper was accessible. We have not invented a response percentage from the words “significantly more effective.”
For someone balancing treatment with work, travel time and clinic access may matter as much as the number of sessions. Ask the treating service what attendance is required for its actual protocol, how progress is assessed, what happens if a session is missed and when an alternative would be considered. Our phototherapy scheduling guide addresses those logistics, while noting that its narrowband-UVB discussion is a different modality.
UVA1 evidence cannot be borrowed from UVB studies
UVA1 and narrowband UVB use different parts of the ultraviolet spectrum. Results and safety estimates cannot simply be transferred between them. Our review of UVB and skin-cancer studies explains uncertainties in that separate evidence base; it does not establish a UVA1 risk estimate for these 28 patients.
The AAD’s dyshidrotic-eczema guidance describes supervised light treatment as a possible option and explicitly discourages trying to substitute unprotected outdoor exposure or tanning beds. Tell the clinic about all prescription medicines and skin products before starting. For example, the tacrolimus label advises against ultraviolet light therapy during treatment. Do not combine treatments independently because two separate studies looked promising.
Start with the diagnosis and the job your hands need to do
Recurring palm blisters can coexist with irritation, allergy or troublesome sweating. A clinician should decide which problems need assessment rather than assuming the word “dyshidrotic” explains the cause. Our hand-blister guide and separate sweating questions help organize that conversation.
Bring a practical outcome to follow: grip comfort, ability to complete necessary hand hygiene, or fewer interruptions to work. Ask when to contact the team if skin worsens and what the care plan should be between appointments. Those individual instructions are more useful than copying a joule dose from a historical paper.
Dr. Arsy Moisturizer #003, 4 oz offers cosmetic hydration, moisture-barrier support and ordinary dry-skin comfort. It was not studied in this trial, is not a sunscreen or eczema medicine, and does not make ultraviolet exposure safe. Ask the clinic which products to use and when relative to supervised sessions.
Adult education; sources checked November 9, 2026. The AI-created badminton scene is illustrative product photography, not an image of a patient or medical procedure.